Figure 2 | Scientific Reports

Figure 2

From: AXL inhibition improves BRAF-targeted treatment in melanoma

Figure 2

Ex vivo response to AXLi treatment in disaggregated cells from melanoma lymph node metastases. Cell viability of lymph node metastases cultured ex vivo and treated with 2 µM BRAFi, 3 µM AXLi or a combination of both drugs for five days. The treatment effect was scored by CTG assay and presented as % relative to the non-treated control set to 100% (Average ± SEM, n = 9).

Back to article page